title: [Problems in microbial safety of advanced therapy medicinal products. Squaring the circle].
abstract: Today, sterility of parenteral drugs is practically guaranteed. Well-defined procedures in the pharmaceutical industry enable effective protection against contamination by bacteria and fungi. In contrast, problems regarding microbial safety of advanced therapy medicinal products (ATMPs), especially of cell therapeutics, are at best only partially solved. The latter should be understood as a challenge for manufacturers, regulators, and physicians. Many of the manufacturing principles mentioned above are not applicable in production of cell therapeutics. Sterility of source materials cannot be guaranteed and the hitherto known procedures for sterilization are, as a rule, not feasible. Thus, the sterility of the final product cannot be guaranteed. Considering the extremely short shelf life of many cell therapeutics, sometimes only a few hours, the results from established methods for sterility testing are often available too late. Furthermore, the sterility of a test sample does not indicate sterility of the whole product. In most cases, conventional methods for pyrogen testing are not applicable for ATMPs. This paper demonstrates relevant limitations regarding microbial safety and pyrogenicity. Possibilities to overcome these problems are discussed and some novel solutions are proposed.
authors.affiliation: Fachgebiet Mikrobielle Sicherheit, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225, Langen. month@pei.de
authors.forename: T
authors.initials: T
authors.lastname: Montag-Lessing
authors.forename: M
authors.initials: M
authors.lastname: Störmer
authors.forename: U
authors.initials: U
authors.lastname: Schurig
authors.forename: J
authors.initials: J
authors.lastname: Brachert
authors.forename: M
authors.initials: M
authors.lastname: Bubenzer
authors.forename: U
authors.initials: U
authors.lastname: Sicker
authors.forename: R
authors.initials: R
authors.lastname: Beshir
authors.forename: I
authors.initials: I
authors.lastname: Spreitzer
authors.forename: B
authors.initials: B
authors.lastname: Löschner
authors.forename: C
authors.initials: C
authors.lastname: Bache
authors.forename: B
authors.initials: B
authors.lastname: Becker
authors.forename: C K
authors.initials: CK
authors.lastname: Schneider
mesh_terms: D001688:Biological Products / Q000592:standards*; D001691:Biological Therapy / Q000592:standards*; D017690:Cell Transplantation / Q000331:legislation & jurisprudence* / Q000592:standards*; D003257:Consumer Product Safety / Q000331:legislation & jurisprudence* / Q000592:standards*; D004340:Drug Contamination / Q000331:legislation & jurisprudence* / Q000517:prevention & control; D005858:Germany; D006801:Humans; D011785:Quality Assurance, Health Care / Q000331:legislation & jurisprudence; D013242:Sterilization / Q000331:legislation & jurisprudence*; D023822:Tissue Engineering / Q000331:legislation & jurisprudence* / Q000592:standards*
chemical_list: D001688:Biological Products